{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:05:17Z","timestamp":1794585917168,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006058","name":"St. Baldrick\u2019s Foundation","doi-asserted-by":"publisher","award":["Scholar award"],"award-info":[{"award-number":["Scholar award"]}],"id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>B cell-activating factor (BAFF) binds the three receptors BAFF-R, BCMA, and TACI, predominantly expressed on mature B cells. Almost all B cell cancers are reported to express at least one of these receptors. Here we develop a BAFF ligand-based chimeric antigen receptor (CAR) and generate BAFF CAR-T cells using a non-viral gene delivery method. We show that BAFF CAR-T cells bind specifically to each of the three BAFF receptors and are effective at killing multiple B cell cancers, including mantle cell lymphoma (MCL), multiple myeloma (MM), and acute lymphoblastic leukemia (ALL), in vitro and in vivo using different xenograft models. Co-culture of BAFF CAR-T cells with these tumor cells results in induction of activation marker CD69, degranulation marker CD107a, and multiple proinflammatory cytokines. In summary, we report a ligand-based BAFF CAR-T capable of binding three different receptors, minimizing the potential for antigen escape in the treatment of B cell cancers.<\/jats:p>","DOI":"10.1038\/s41467-021-27853-w","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T06:02:51Z","timestamp":1641880971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-1333","authenticated-orcid":false,"given":"Derek P.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nand K.","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keman","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-4331","authenticated-orcid":false,"given":"Anusha","family":"Anukanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Asthana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole J.","family":"Shirkey-Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Dunmire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9863-7119","authenticated-orcid":false,"given":"Bryan J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walker S.","family":"Lahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-8747","authenticated-orcid":false,"given":"Beau R.","family":"Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branden S.","family":"Moriarity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8043-7450","authenticated-orcid":false,"given":"Reshmi","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"27853_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 15, 31\u201346 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"27853_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. New Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"New Engl. J. Med."},{"key":"27853_CR3","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. New Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"New Engl. J. Med."},{"key":"27853_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","volume":"10","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer, J. N. & Rosenberg, S. A. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10, 267\u2013276 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"27853_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak, A. J. et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103, 689\u2013694 (2004).","journal-title":"Blood"},{"key":"27853_CR6","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","volume":"126","author":"M Ruella","year":"2016","unstructured":"Ruella, M. et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J. Clin. Invest. 126, 3814\u20133826 (2016).","journal-title":"J. Clin. Invest."},{"key":"27853_CR7","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282\u20131295 (2015).","journal-title":"Cancer Discov."},{"key":"27853_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/bjh.13562","volume":"171","author":"AG Evans","year":"2015","unstructured":"Evans, A. G. et al. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br. J. Haematol. 171, 205\u2013209 (2015).","journal-title":"Br. J. Haematol."},{"key":"27853_CR9","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127, 2406\u20132410 (2016).","journal-title":"Blood"},{"key":"27853_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"27853_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbmt.2016.09.002","volume":"23","author":"SS Kenderian","year":"2017","unstructured":"Kenderian, S. S., Porter, D. L. & Gill, S. Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse. Biol. Blood Marrow Transplant. 23, 235\u2013246 (2017).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"27853_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh, M. et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112\u2013116 (2019).","journal-title":"Nature"},{"key":"27853_CR13","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali, S. A. et al. T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688\u20131700 (2016).","journal-title":"Blood"},{"key":"27853_CR14","doi-asserted-by":"publisher","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984 (2017).","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"27853_CR15","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. New Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"New Engl. J. Med."},{"key":"27853_CR16","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"27853_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.beha.2018.03.003","volume":"31","author":"JM Murad","year":"2018","unstructured":"Murad, J. M., Graber, D. J. & Sentman, C. L. Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies. Best. Pract. Res. Clin. Haematol. 31, 176\u2013183 (2018).","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"27853_CR18","doi-asserted-by":"publisher","unstructured":"Hughes-Parry, H. E., Cross, R. S. & Jenkins, M. R. The evolving protein engineering in the design of chimeric antigen receptor T cells. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21010204 (2019).","DOI":"10.3390\/ijms21010204"},{"key":"27853_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/annonc\/mdx755","volume":"29","author":"J Tang","year":"2018","unstructured":"Tang, J., Shalabi, A. & Hubbard-Lucey, V. M. Comprehensive analysis of the clinical immuno-oncology landscape. Ann. Oncol. 29, 84\u201391 (2018).","journal-title":"Ann. Oncol."},{"key":"27853_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","volume":"21","author":"F Mackay","year":"2003","unstructured":"Mackay, F., Schneider, P., Rennert, P. & Browning, J. BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231\u2013264 (2003).","journal-title":"Annu. Rev. Immunol."},{"key":"27853_CR21","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1535-7163.MCT-13-1023","volume":"13","author":"R Parameswaran","year":"2014","unstructured":"Parameswaran, R. et al. Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R. Mol. Cancer Ther. 13, 1567\u20131577 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"27853_CR22","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/0008-5472.CAN-10-0300","volume":"70","author":"R Parameswaran","year":"2010","unstructured":"Parameswaran, R., Muschen, M., Kim, Y. M., Groffen, J. & Heisterkamp, N. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res. 70, 4346\u20134356 (2010).","journal-title":"Cancer Res."},{"key":"27853_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/eji.201141957","volume":"42","author":"R Tussiwand","year":"2012","unstructured":"Tussiwand, R., Rauch, M., Fluck, L. A. & Rolink, A. G. BAFF-R expression correlates with positive selection of immature B cells. Eur. J. Immunol. 42, 206\u2013216 (2012).","journal-title":"Eur. J. Immunol."},{"key":"27853_CR24","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/blood-2004-02-0762","volume":"104","author":"AJ Novak","year":"2004","unstructured":"Novak, A. J. et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104, 2247\u20132253 (2004).","journal-title":"Blood"},{"key":"27853_CR25","doi-asserted-by":"publisher","unstructured":"Yarchoan, M. et al. Effects of B cell-activating factor on tumor immunity. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.136417 (2020).","DOI":"10.1172\/jci.insight.136417"},{"key":"27853_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"S Guedan","year":"2019","unstructured":"Guedan, S., Calderon, H., Posey, A. D. Jr. & Maus, M. V. Engineering and design of chimeric antigen receptors. Mol. Ther. Methods Clin. Dev. 12, 145\u2013156 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"27853_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3109\/08830185.2015.1018419","volume":"34","author":"JA Figueroa","year":"2015","unstructured":"Figueroa, J. A. et al. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Int. Rev. Immunol. 34, 154\u2013187 (2015).","journal-title":"Int. Rev. Immunol."},{"key":"27853_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/1050-1738(95)00127-1","volume":"6","author":"M Qazilbash","year":"1996","unstructured":"Qazilbash, M., Young, N. & Liu, J. Vectors and target cells for gene therapy of blood diseases. Trends Cardiovasc. Med. 6, 25\u201330 (1996).","journal-title":"Trends Cardiovasc. Med."},{"key":"27853_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrg3763","volume":"15","author":"H Yin","year":"2014","unstructured":"Yin, H. et al. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541\u2013555 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"27853_CR30","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","volume":"126","author":"P Kebriaei","year":"2016","unstructured":"Kebriaei, P. et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J. Clin. Invest. 126, 3363\u20133376 (2016).","journal-title":"J. Clin. Invest."},{"key":"27853_CR31","doi-asserted-by":"publisher","unstructured":"Magnani, C. F. et al. Transposon-based CAR T cells in acute leukemias: where are we going? Cells https:\/\/doi.org\/10.3390\/cells9061337 (2020).","DOI":"10.3390\/cells9061337"},{"key":"27853_CR32","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1101\/gr.6286907","volume":"17","author":"GP Wang","year":"2007","unstructured":"Wang, G. P., Ciuffi, A., Leipzig, J., Berry, C. C. & Bushman, F. D. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 17, 1186\u20131194 (2007).","journal-title":"Genome Res."},{"key":"27853_CR33","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1097\/QAD.0b013e32832caf28","volume":"23","author":"T Brady","year":"2009","unstructured":"Brady, T. et al. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 23, 1461\u20131471 (2009).","journal-title":"AIDS"},{"key":"27853_CR34","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/mt.2016.11","volume":"24","author":"A Gogol-Doring","year":"2016","unstructured":"Gogol-Doring, A. et al. Genome-wide profiling reveals remarkable parallels between insertion site selection properties of the MLV retrovirus and the piggyBac transposon in primary human CD4(+) T cells. Mol. Ther. 24, 592\u2013606 (2016).","journal-title":"Mol. Ther."},{"key":"27853_CR35","doi-asserted-by":"crossref","unstructured":"Rihacek, M. et al. B-cell activating factor as a cancer biomarker and its implications in cancer-related cachexia. Biomed. Res. Int. 2015, 792187 (2015).","DOI":"10.1155\/2015\/792187"},{"key":"27853_CR36","doi-asserted-by":"publisher","first-page":"e01047","DOI":"10.1002\/cti2.1047","volume":"8","author":"FB Vincent","year":"2019","unstructured":"Vincent, F. B. et al. Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. Clin. Transl. Immunol. 8, e01047 (2019).","journal-title":"Clin. Transl. Immunol."},{"key":"27853_CR37","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez, E. et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158, 727\u2013738 (2012).","journal-title":"Br. J. Haematol."},{"key":"27853_CR38","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","volume":"9","author":"CR Smulski","year":"2018","unstructured":"Smulski, C. R. & Eibel, H. BAFF and BAFF-receptor in B cell selection and survival. Front. Immunol. 9, 2285 (2018).","journal-title":"Front. Immunol."},{"key":"27853_CR39","doi-asserted-by":"publisher","first-page":"e20787","DOI":"10.1371\/journal.pone.0020787","volume":"6","author":"S Maia","year":"2011","unstructured":"Maia, S. et al. Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS ONE 6, e20787 (2011).","journal-title":"PLoS ONE"},{"key":"27853_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0337-y","volume":"10","author":"A Dogan","year":"2020","unstructured":"Dogan, A. et al. B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer J. 10, 73 (2020).","journal-title":"Blood Cancer J."},{"key":"27853_CR41","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.3389\/fimmu.2018.02486","volume":"9","author":"K Watanabe","year":"2018","unstructured":"Watanabe, K., Kuramitsu, S., Posey, A. D. Jr. & June, C. H. Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology. Front. Immunol. 9, 2486 (2018).","journal-title":"Front. Immunol."},{"key":"27853_CR42","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"27853_CR43","doi-asserted-by":"publisher","first-page":"10679","DOI":"10.1073\/pnas.97.20.10679","volume":"97","author":"J Foote","year":"2000","unstructured":"Foote, J. & Eisen, H. N. Breaking the affinity ceiling for antibodies and T cell receptors. Proc. Natl Acad. Sci. USA 97, 10679\u201310681 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"27853_CR44","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-08-0461","volume":"68","author":"X Du","year":"2008","unstructured":"Du, X., Beers, R., Fitzgerald, D. J. & Pastan, I. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res. 68, 6300\u20136305 (2008).","journal-title":"Cancer Res."},{"key":"27853_CR45","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.coi.2010.09.010","volume":"22","author":"A Davidson","year":"2010","unstructured":"Davidson, A. Targeting BAFF in autoimmunity. Curr. Opin. Immunol. 22, 732\u2013739 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"27853_CR46","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918\u20133930 (2011).","journal-title":"Arthritis Rheum."},{"key":"27853_CR47","doi-asserted-by":"publisher","unstructured":"Qin, H. et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaw9414 (2019).","DOI":"10.1126\/scitranslmed.aaw9414"},{"key":"27853_CR48","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3389\/fimmu.2019.01613","volume":"10","author":"M Timmers","year":"2019","unstructured":"Timmers, M. et al. Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen. Front. Immunol. 10, 1613 (2019).","journal-title":"Front. Immunol."},{"key":"27853_CR49","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","volume":"131","author":"L Lee","year":"2018","unstructured":"Lee, L. et al. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Blood 131, 746\u2013758 (2018).","journal-title":"Blood"},{"key":"27853_CR50","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","volume":"3","author":"A Schmidts","year":"2019","unstructured":"Schmidts, A. et al. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 3, 3248\u20133260 (2019).","journal-title":"Blood Adv."},{"key":"27853_CR51","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1182\/blood-2018-99-117296","volume":"132","author":"Y-T Tai","year":"2018","unstructured":"Tai, Y.-T. et al. APRIL is significantly elevated at all stages of multiple myeloma (MM) and interferes with anti-bcma monoclonal antibody-mediated cytolysis, supporting the clinical evaluation of bion-1301 as a novel therapeutic approach in MM. Blood 132, 3209\u20133209 (2018).","journal-title":"Blood"},{"key":"27853_CR52","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4049\/jimmunol.1402070","volume":"194","author":"FS Hoffmann","year":"2015","unstructured":"Hoffmann, F. S. et al. The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity. J. Immunol. 194, 542\u2013552 (2015).","journal-title":"J. Immunol."},{"key":"27853_CR53","doi-asserted-by":"publisher","first-page":"e0185056","DOI":"10.1371\/journal.pone.0185056","volume":"12","author":"B Bushnell","year":"2017","unstructured":"Bushnell, B., Rood, J. & Singer, E. BBMerge - accurate paired shotgun read merging via overlap. PLoS ONE 12, e0185056 (2017).","journal-title":"PLoS ONE"},{"key":"27853_CR54","doi-asserted-by":"publisher","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal https:\/\/doi.org\/10.14806\/ej.17.1.200 (2011).","DOI":"10.14806\/ej.17.1.200"},{"key":"27853_CR55","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"27853_CR56","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1101\/gr.849004","volume":"14","author":"GE Crooks","year":"2004","unstructured":"Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res. 14, 1188\u20131190 (2004).","journal-title":"Genome Res."},{"key":"27853_CR57","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1093\/bioinformatics\/btr539","volume":"27","author":"RK Dale","year":"2011","unstructured":"Dale, R. K., Pedersen, B. S. & Quinlan, A. R. Pybedtools: a flexible Python library for manipulating genomic datasets and annotations. Bioinformatics 27, 3423\u20133424 (2011).","journal-title":"Bioinformatics"},{"key":"27853_CR58","doi-asserted-by":"publisher","first-page":"D493","DOI":"10.1093\/nar\/gkh103","volume":"32","author":"D Karolchik","year":"2004","unstructured":"Karolchik, D. et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res. 32, D493\u2013D496 (2004).","journal-title":"Nucleic Acids Res."},{"key":"27853_CR59","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2326-6066.CIR-19-0058","volume":"7","author":"Y Vicioso","year":"2019","unstructured":"Vicioso, Y. et al. Combination therapy for treating advanced drug-resistant acute lymphoblastic leukemia. Cancer Immunol. Res. 7, 1106\u20131119 (2019).","journal-title":"Cancer Immunol. Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27853-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27853-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27853-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T10:44:17Z","timestamp":1669286657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27853-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["27853"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-27853-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"6 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.S. and S.D. are employees of Luminary Therapeutics. R.P. is a consultant for Luminary therapeutics. B.J.J. is an employee at Bio-Techne. B.R.W. and B.S.M. are consultants for Bio-Techne and are shareholders of Luminary Therapeutics. P.C. is a member of advisory board of ADC therapeutics and have received honoraria from kite pharma. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}